Baez-Vallecillo, Luis
Raghavendra, Akshara S.
Hess, Kenneth R.
Barcenas, Carlos H.
Moulder, Stacy L.
Tripathy, Debu
Valero, Vicente
Murthy, Rashmi K. http://orcid.org/0000-0002-0103-4718
Funding for this research was provided by:
National Cancer Institute (P30CA016672)
Article History
Received: 25 May 2018
Accepted: 3 December 2018
First Online: 11 April 2019
Compliance with ethical standards
:
: Luiz Baez-Vallecillo, Akshara S. Raghavendra, Kenneth R. Hess, Carlos H. Barcenas, and Vicente Valero report no conflict of interest relevant to this work. Stacy L. Moulder serves or has served as a consultant for Novartis, Oncothyreon, Pfizer, and Immunogenics. Debu Tripathy serves as a consultant for Novartis and Pfizer, and also receives funding from Novartis. Rashmi K. Murthy receives research funding from Cascadian therapeutics, Daiichi Sankyo, Gnentech, and Pfizer (all in research support paid to the institution).
: This article does not contain any studies with human participants or animals.
: This study was approved by the institutional review board at MD Anderson Cancer Center, and waivers for obtaining informed consent were granted.